Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.56 |
| ▸ | CCND1 | P24385 | 4/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 4/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28783985 | 0.98 | CDK4 (0.55) | CDK4CCND1HTR2AHTR2CHTR6 | |
| Hydrochloric Acid SCHEMBL28867138 | 0.98 | CDK4 (0.55) | CDK4CCND1HTR2AHTR2CHTR6 | |
| Water SCHEMBL28867163 | 0.89 | HTT (0.52) | CDK4CCND1HTR2AHTR2CHTR6 | |
| Ethoxycarbonyl Group SCHEMBL27767556 | 0.85 | CDK4 (0.42) | CDK4CCND1HTR2AHTR2CHTR6 | |
| SCHEMBL7052509 | 0.84 | CDK4 (0.57) | CDK4CCND1HTR2AHTR2CHTR6 | |
| SCHEMBL4828100 | 0.84 | CDK4 (0.57) | CDK4CCND1HTR2AHTR2CHTR6 | |
| SCHEMBL4896448 | 0.83 | CDK4 (0.55) | CDK4CCND1HTR2AHTR2CHTR6 | |
| SCHEMBL5944315 | 0.80 | CDK4 (0.52) | CDK4CCND1HTR2AHTR2CHTR6 | |
| SCHEMBL30041985 | 0.80 | CDK4 (0.52) | CDK4CCND1HTR2AHTR2CHTR6 | |
| SCHEMBL3205958 | 0.80 | CDK4 (0.52) | CDK4CCND1HTR2AHTR2CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109152751-A | Pure 5-HT6Triple combination of receptor antagonist, acetylcholinesterase inhibitor and NMDA receptor antagonist | 苏文生命科学有限公司 | 2019-01-04 | — | — | CN | claimed |
| CN-109069449-A | Pure 5-HT6The combination of receptor antagonist and nmda receptor antagonist | 苏文生命科学有限公司 | 2018-12-21 | — | — | CN | claimed |
| EP-2121602-B1 | 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL) INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-03-18 | — | — | EP | disclosed |
| CN-101563321-B | 4- (heterocyclyl) alkyl-N- (arylsulfonyl) indole compounds and their use as 5-HT6Use of ligands | SUVEN LIFE SCIENCES LTD | 2012-05-30 | — | — | CN | disclosed |
| US-7781476-B2 | Serotonin and melatonergic ligands such as 10-(4-Methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide, used for the treatment of psychological disorders, side effect reduction of antipsychotic drugs, neurodegenerative disorders, chemotherapy-induced vomiting and eating disorders | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-08-24 | — | — | US | disclosed |
| US-20100041669-A1 | 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-02-18 | — | — | US | disclosed |
| EP-2121602-A1 | 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL) INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | Suven Life Sciences Limited (IN) | 2009-11-25 | — | — | EP | disclosed |
| CN-101563321-A | 4- (heterocyclyl) alkyl-N- (arylsulfonyl) indole compounds and their use as 5-HT6Use of ligands | SUVEN LIFE SCIENCES LTD (IN) | 2009-10-21 | — | — | CN | disclosed |
| WO-2008084491-A1 | 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL) INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2008-07-17 | — | — | WO | disclosed |
| US-20070142398-A1 | Tetracyclic 3-substituted indoles having serotonin receptor affinity | SUVEN LIFE SCIENCES LIMITED (IN) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142398-A1 | Tetracyclic 3-substituted indoles having serotonin receptor affinity | HTR3A, HTR3C, HTR3B | CDK4 2939/4885CCND1 3368/4885HTR2A 8/4885 |
| US-20100041669-A1 | 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR5A, HTR1A | CDK4 1064/4885CCND1 1836/4885HTR2A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.